U.S.-Japan trade pact; Alphabet, Tesla to report - what’s moving markets
Investing.com -- Roche Holding AG (OTC:RHHVF) on Monday reported mixed results from late-stage trials for its experimental drug astegolimab, which is being developed to treat chronic obstructive pulmonary disease (COPD).
According to a statement released Monday, the drug showed a 15.4% reduction in worsening of the condition, known as exacerbations, in a phase 2b study. However, astegolimab failed to meet its goal in another trial.
Levi Garraway, Roche’s chief medical officer and head of global product development, said: "This was the first set of studies in an ’all-comers’ COPD population, and we will discuss these data with regulatory authorities to evaluate next steps for astegolimab."
The mixed results represent a setback for the company as it works to accelerate the development of new treatments for the deadly lung condition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.